GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Avenue Therapeutics
Avenue Therapeutics is a biopharmaceutical company whose stock price reflects its long and arduous battle to secure FDA approval for its pain medication. The chart exemplifies the high regulatory risks in the biotech sector.
Share prices of companies in the market segment - Neuro
Avenue Therapeutics is a pharmaceutical company specializing in developing drugs for the treatment of central nervous system disorders. We've categorized it under the "Neurology" category. The chart below shows how investors value companies in this complex area of medicine.
Broad Market Index - GURU.Markets
Avenue Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of diseases of the central nervous system. As a component of the GURU.Markets index, it represents the neuroscience sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ATXI - Daily change in the company's share price Avenue Therapeutics
For Avenue Therapeutics, Inc., a pharmaceutical company, daily volatility reflects sensitivity to FDA decisions. This metric is key to assessing the company's risk after receiving regulatory waivers.
Daily change in the price of a set of shares in a market segment - Neuro
Avenue Therapeutics develops drugs for the treatment of neurological diseases, particularly for inpatient use. This is a highly specialized and risky niche. The chart below shows the volatility in the pharmaceutical sector, reflecting the stakes associated with new drug development.
Daily change in the price of a broad market stock, index - GURU.Markets
Avenue Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Avenue Therapeutics
Avenue Therapeutics' year-to-date performance is the story of its years-long battle for FDA approval of its intranasal tramadol. Its market capitalization over the past 12 months is crucially dependent on regulatory news. This latest rejection was a serious blow, and now its valuation reflects investors' faith in the company's ability to find a new path.
Annual dynamics of market capitalization of the market segment - Neuro
Avenue, a late-stage biotech company, develops drugs for the treatment of neurological diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avenue Therapeutics, a pharmaceutical company developing drugs for hospital use, is focused on a narrow market segment. Its annual market capitalization dynamics depend on FDA decisions and its ability to commercialize its products in the hospital environment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Avenue Therapeutics
Avenue is a late-stage biopharmaceutical company. Its monthly performance is extremely sensitive to regulatory decisions. FDA news regarding its lead drug can cause multiple price changes in a short period of time.
Monthly dynamics of market capitalization of the market segment - Neuro
Avenue Therapeutics develops drugs for hospital use, particularly for pain relief. This pharmaceutical segment faces stringent regulatory requirements and competition. The chart below shows how investors assessed the prospects of companies attempting to bring new drugs to market for hospital use.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avenue Therapeutics is a small pharmaceutical company. Its shares, like many in the sector, are highly sensitive to regulatory decisions (such as the FDA). Positive or negative news can trigger sharp and unpredictable movements unrelated to the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Avenue Therapeutics
Shares of Avenue Therapeutics, a biopharmaceutical company, are extremely news-sensitive. Weekly price movements depend entirely on FDA regulatory decisions regarding their pain medications. The chart below illustrates how regulatory decisions trigger sharp price fluctuations, which is typical for late-stage pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Neuro
Avenue Therapeutics develops drugs for hospital use. This market has different regulations than retail pharmaceuticals. The chart shows how news about clinical trials and potential regulatory approvals impact the company's stock, creating its own unique path.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Avenue Therapeutics is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
ATXI - Market capitalization of the company Avenue Therapeutics
Avenue Therapeutics' price chart reflects its years-long quest to secure FDA approval for its injectable drug, tramadol. The company's market cap reflects investor skepticism after several regulatory rejections. The dynamics illustrate how regulatory risks can weigh on a biotech company's valuation.
ATXI - Share of the company's market capitalization Avenue Therapeutics within the market segment - Neuro
Avenue Therapeutics's stake in the neuroscience sector is focused on the development and commercialization of drugs for the treatment of acute pain. Its market share reflects its efforts to secure approval for its injectable tramadol, which could become an alternative to traditional opioids in hospital settings.
Market capitalization of the market segment - Neuro
The chart shows the aggregate market capitalization of small pharmaceutical companies. Avenue Therapeutics is an example of such a player. The chart's dynamics reflect high volatility and risks associated with clinical trials and regulatory decisions.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of acute pain management. Avenue Therapeutics' market capitalization is a valuation of its pharmaceutical developments in this area. The line shows the roller coaster of clinical trials and investor hopes that the company will be able to capture its share of the gigantic pain relief market.
Book value capitalization of the company, segment and market as a whole
ATXI - Book value capitalization of the company Avenue Therapeutics
Avenue Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments targeting central nervous system diseases. The pipeline's growth reflects success in clinical trials and partnerships, which are the company's primary assets.
ATXI - Share of the company's book capitalization Avenue Therapeutics within the market segment - Neuro
Avenue Therapeutics' tangible assets are its R&D infrastructure, which is focused on developing drugs for the treatment of central nervous system diseases. The chart shows its share of this scientific base, which forms the foundation of its pharmaceutical programs.
Market segment balance sheet capitalization - Neuro
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Avenue Therapeutics, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Avenue Therapeutics is a pharmaceutical company specializing in drugs for the treatment of neurological diseases. Its assets include a patent portfolio and clinical trial data. The chart shows the financial resources devoted to finding solutions for complex diseases of the nervous system.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Avenue Therapeutics
Avenue Therapeutics is a small pharmaceutical company trying to bring a painkiller to market. Its book value is minimal. The chart below is a history of its regulatory battles. Its movements will reflect not the state of its assets, but news from the FDA, whose decisions will determine the company's fate.
Market to book capitalization ratio in a market segment - Neuro
Avenue Therapeutics, Inc. is a pharmaceutical company specializing in developing drugs for the treatment of central nervous system diseases. Its value depends on the success of its clinical programs. This chart shows how its market valuation is a bet on the future.
Market to book capitalization ratio for the market as a whole
Avenue Therapeutics develops drugs for the treatment of neurological diseases, particularly acute pain. Its market valuation, as shown in this chart, depends on its success in obtaining regulatory approval for its products. It is a biotech with a high degree of regulatory risk.
Debts of the company, segment and market as a whole
ATXI - Company debts Avenue Therapeutics
Avenue Therapeutics, a late-stage pharmaceutical company, is using raised capital to pursue FDA approval for its pain medication. This chart tells the story of the company's long and arduous battle with the regulator, which requires constant funding for additional research.
Market segment debts - Neuro
Avenue Therapeutics is a biopharmaceutical company facing significant challenges after the FDA denied approval of its lead drug. This chart shows how its debt policy reflects this challenging situation and how it manages its remaining capital in search of a new strategic path for survival.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Avenue Therapeutics
Ault Alliance is a diversified holding company with investments in a wide range of sectors, from Bitcoin mining to defense technology. This chart shows the total debt load of this complex entity, reflecting the company's aggressive and high-risk investment strategy.
Market segment debt to market segment book capitalization - Neuro
Avenue Therapeutics is a specialty pharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how a small company finances its clinical research.
Debt to book value of all companies in the market
Avenue Therapeutics, a subsidiary of Fortress Biotech, develops drugs to treat neurological diseases. Funding biotech startups is risky. This chart of total market debt provides insight into the availability of capital needed to conduct clinical trials and bring new drugs to market.
P/E of the company, segment and market as a whole
P/E - Avenue Therapeutics
For Avenue Therapeutics, a pharmaceutical company, the P/E ratio is irrelevant. The company doesn't have stable profits. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' faith in the success of its clinical trials.
P/E of the market segment - Neuro
Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing drugs for hospital use, particularly in neurology. This chart shows the average valuation for the neurology sector, reflecting how investors value companies operating in the hospital drug market.
P/E of the market as a whole
Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing drugs for hospital use, particularly in pain management. This chart, reflecting overall sentiment, helps understand how investors value smaller, niche pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company focused on developing therapeutics for hospital use. This graph reflects market expectations for the success of its developments. Future revenue is dependent on regulatory approval and commercialization of its products.
%20P%2FE%20Avenue%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Avenue-Therapeutics&v=1772662146649 "Chart of the company's future (projected) P/E Avenue Therapeutics")
Future (projected) P/E of the market segment - Neuro
Avenue Therapeutics develops drugs for use in critical care settings. This chart shows how investors assess its chances of obtaining approval and commercializing its products. It compares Avenue's expectations with those of other late-stage pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772662146704 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Avenue Therapeutics, a subsidiary of Fortress Biotech, is developing drugs for the treatment of neurological diseases. Its success depends on clinical trial results and regulatory approval. The overall market optimism shown by this chart is important for attracting the capital needed to advance research in this complex area of medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772662146766 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company focused on developing therapeutics for hospital use. Its financial performance depends on successful clinical trials and FDA approval. This chart illustrates the company's financial trajectory as it strives to bring new medical solutions to market for hospitals.
Profit of companies in the market segment - Neuro
Avenue Therapeutics, a subsidiary of Fortress Biotech, specializes in developing drugs for the treatment of central nervous system diseases. This graph, showing overall sector profitability, reflects the complexity and potential of neuroscience. Success in Avenue's clinical programs could lead to new treatments and impact the entire pharmaceutical industry.
Overall market profit
Avenue Therapeutics develops drugs for the treatment of central nervous system diseases. The company focuses on finding solutions to unmet medical needs. Its success, like that of other biotech companies, depends on the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Avenue Therapeutics
Avenue Therapeutics develops drugs for the treatment of neurological diseases. Future revenue projections are speculative and depend on the results of clinical trials and FDA approval of its products.
%20profit%20of%20the%20company%20Avenue%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Avenue-Therapeutics&v=1772662147001 "Graph of future (projected) profit of the company Avenue Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Avenue Therapeutics develops drugs for hospital use, particularly for the treatment of acute pain. This chart shows revenue forecasts for the entire pharmaceutical sector. It helps understand how the company's hospital-focused product compares to overall healthcare trends and hospital needs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772662147066 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Avenue Therapeutics develops medications for inpatient use. Demand for these products is driven by medical necessity. However, this timing is important because it impacts the financial health of hospitals—the company's primary clients. During periods of economic growth, they have greater opportunities to purchase new and more effective medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772662147081 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company focused on developing drugs for hospital use. This chart, plotting its market capitalization against near-zero revenue, reflects its difficulties in obtaining regulatory approval. It shows how investors view its diminished chances of commercial success.
P/S market segment - Neuro
Avenue Therapeutics, a subsidiary of Fortress Biotech, specializes in the development and commercialization of drugs for hospital use, particularly in pain management. This chart reflects investor estimates of pharmaceutical revenue, reflecting expectations for the approval and commercial success of Avenue Therapeutics' products.
P/S of the market as a whole
Avenue Therapeutics, a subsidiary of Fortress Biotech, focuses on developing and commercializing therapeutics for hospital use, particularly for the treatment of acute pain. This chart, which displays the average valuation, shows that investors value the company based on the potential of its products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Avenue Therapeutics
Avenue Therapeutics is a pharmaceutical company specializing in hospital-based therapies. This chart shows the market's assessment of its potential future revenue. It reflects investor confidence in the success of its clinical programs and its ability to secure regulatory approval for its products.
%20P%2FS%20Avenue%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Avenue-Therapeutics&v=1772662147182 "The graph of the company's future (projected) P/S Avenue Therapeutics")
Future (projected) P/S of the market segment - Neuro
Avenue Therapeutics, a subsidiary of Fortress Biotech, develops and commercializes drugs for inpatient use. The chart shows the average estimated future sales in the neuroscience sector. It helps understand how investors view the company's current developments and its chances of obtaining regulatory approval and successfully launching them.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772662147206 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Avenue Therapeutics (ATXI) is a pharmaceutical company focused on developing drugs for the central nervous system. Their future depends on the success of clinical trials and regulatory approval. This graph of general economic expectations is irrelevant for a company operating in a highly specialized field of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772662147217 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Avenue Therapeutics
Avenue Therapeutics is a pharmaceutical company focused on developing drugs for hospital use. While it is in the approval stage, it does not yet have stable sales revenue. Future trends in this revenue curve will depend on the commercial launch of its acute pain treatment products.
Sales of companies in the market segment - Neuro
Avenue Therapeutics is a pharmaceutical company focused on developing drugs for the central nervous system. Following the failure of its lead candidate, its future revenue will depend on the success of new assets it may acquire or develop, reflecting the risks and transformations in the biotech industry.
Overall market sales
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on hospital-based medications. Its success depends on the approval and acceptance of its products by the medical community. Demand for hospital-based medications is inelastic, but the overall economic situation, shown in this chart, influences hospital budgets and their purchasing policies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Avenue Therapeutics
Avenue Therapeutics develops medications for hospital use, particularly for pain relief. Future revenue depends on the approval and commercialization of its products. This chart reflects analysts' long-term expectations for its pipeline.
%20sales%20of%20the%20company%20Avenue%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Avenue-Therapeutics&v=1772662147372 "Schedule of future (projected) sales of the company Avenue Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Avenue Therapeutics, a subsidiary of Fortress Biotech, develops drugs for the treatment of neurological diseases. This chart shows the outlook for the neurological sector. It reflects the significant unmet need for effective and safe treatments for acute pain, a focus for Avenue.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772662147393 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
The pharmaceutical investment climate, illustrated by this chart, is important for Avenue Therapeutics. The company develops drugs for hospital use. Its success in commercializing its products depends on hospitals' willingness to purchase new drugs, which is determined by their budgets and the overall economic situation.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772662147409 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company focused on developing therapeutics for hospital use. This chart reflects its financial performance during clinical trials and regulatory interactions. Future profitability depends on FDA approval and the commercial success of its products.
Market segment marginality - Neuro
Avenue Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system diseases. Profitability depends on the success of its products in clinical trials and approvals. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential of its developments in the complex field of neurology.
Market marginality as a whole
Avenue Therapeutics develops drugs for inpatient use. The company's commercial success depends on regulatory approval and hospital acceptance of its products. This timeline, reflecting the overall economic situation, impacts healthcare system budgets, which determine how quickly new, even effective, drugs can be incorporated into treatment protocols.
Employees in the company, segment and market as a whole
Number of employees in the company Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company focused on hospital-based therapies. This chart reflects a very compact team. Their business model often involves licensing or late-stage acquisitions, which requires a small but experienced team to navigate regulatory processes.
Share of the company's employees Avenue Therapeutics within the market segment - Neuro
Avenue Therapeutics, a subsidiary of Fortress Biotech, develops drugs for the treatment of neurological diseases. This chart shows the company's share of the total number of researchers in its therapeutic area. Its dynamics may reflect the stages of clinical trials and staffing needs.
Number of employees in the market segment - Neuro
Avenue Therapeutics is a pharmaceutical company developing drugs for the treatment of neurological diseases. This chart, showing employment in the neuroscience sector, is important. The growing number of neuroscientists and clinicians in this field indicates a high need for new treatments for patients suffering from rare and complex neurological disorders.
Number of employees in the market as a whole
Avenue Therapeutics develops drugs for the treatment of neurological diseases. Funding in this field requires investors to have a long-term vision. This overall occupancy rate reflects the economic stability that allows venture capital and large funds to invest in the complex and lengthy clinical trials necessary for the company's success.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Avenue Therapeutics (ATXI)
Avenue Therapeutics (ATXI) is a pharmaceutical company specializing in acute care medications (e.g., pain relief). This chart shows the valuation of their "intellectual capital." A company's market value is derived from its drug patents and their commercial potential, not its headcount.
%20of%20the%20company%20Avenue%20Therapeutics%20(ATXI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Avenue-Therapeutics-ATXI&v=1772662147669 "Chart of market capitalization per employee (in thousands of dollars) of the company Avenue Therapeutics (ATXI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Avenue Therapeutics is a pharmaceutical company specializing in drugs for the treatment of neurological diseases. Like many development-stage biotech companies, its valuation is based on the potential of its products. This metric illustrates that the market values intellectual property, not the size of its workforce.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772662147749 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Avenue Therapeutics is a specialty pharmaceutical company focused on hospital-based therapies. Its success depends on the approval and commercialization of one or two key products. This chart illustrates how a small team can generate significant market value while operating in a narrow medical niche.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772662147836 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Avenue Therapeutics (ATXI)
Avenue Therapeutics is a specialty pharmaceutical company seeking to commercialize drugs (often in partnership) for the treatment of central nervous system disorders. This chart illustrates how successfully their very small team manages this process, balancing clinical trial costs with potential revenue.
%20Chart%20Avenue%20Therapeutics%20(ATXI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Avenue-Therapeutics-ATXI&v=1772662147860 "Company Profit Per Employee (in thousands of dollars) Chart Avenue Therapeutics (ATXI)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Avenue Therapeutics develops drugs for the treatment of neurological diseases. Like many development-stage biotech companies, it incurs significant expenses on clinical trials. This chart helps assess the effectiveness of its capital management. Positive trends in this indicator will be associated with successful approval and market launch of its products.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772662147913 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Avenue Therapeutics (ATXI) is a biopharmaceutical company specializing in drugs for the treatment of neurological diseases. It is an R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of neurology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772662147935 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Avenue Therapeutics (ATXI)
Avenue Therapeutics develops drugs for hospital use. After the failure of its key product, this graph shows how the company is pursuing new opportunities. Its future dynamics will depend on the success of new developments or acquisitions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Avenue-Therapeutics-ATXI&v=1772662147992 "Sales chart per company employee Avenue Therapeutics (ATXI)")
Sales per employee in the market segment - Neuro
Avenue Therapeutics is a clinical-stage biotech focused on neuroscience drugs, particularly painkillers. It's an R&D company. This chart reflects their clinical stage. Their research team's productivity lies in developing and advancing drug candidates, not in ongoing sales.
Sales per employee for the market as a whole
Harmonic (HLIT) is a technology leader in video delivery and broadband access. They provide hardware and software (SaaS) that enables media companies to stream video and cable operators to provide high-speed internet. This chart illustrates the shift to SaaS. Harmonic is increasingly shifting from selling hardware to software subscriptions (CableOS). This significantly increases revenue per employee as the software scales.
Short shares by company, segment and market as a whole
Shares shorted by company Avenue Therapeutics (ATXI)
Avenue Therapeutics (ATXI) is a biotech company that has received multiple FDA rejections for its pain medication. This chart tracks bearish bets. Shorts reflect the belief that the company will never receive regulatory approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Avenue-Therapeutics-ATXI&v=1772662148229 "Short Shares Chart for the Company Avenue Therapeutics (ATXI)")
Shares shorted by market segment - Neuro
Avenue Therapeutics (ATXI) is a biopharmaceutical company specializing in drugs for neurological diseases. The chart below represents a general short position in the biotech sector. It demonstrates the general investor skepticism regarding the success of risky clinical trials.
Shares shorted by the overall market
Avenue Therapeutics (ATXI) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Avenue Therapeutics (ATXI)
This chart for Avenue Therapeutics is a barometer of regulatory risk. The company has been trying to secure FDA approval for its IV tramadol (pain reliever) for years. "Overheating" (above 70) occurs in anticipation of an FDA decision. Repeated regulatory rejections (CRLs) due to safety concerns keep the stock "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Avenue-Therapeutics-ATXI&v=1772662148402 "RSI 14 indicator chart for the company's stock Avenue Therapeutics (ATXI)")
RSI 14 Market Segment - Neuro
Avenue Therapeutics is a "biotech" and a "pain hunter." Their focus is injectable (IV) tramadol for post-operative pain. The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ATXI's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Avenue Therapeutics (ATXI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATXI (Avenue Therapeutics)
Avenue Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system diseases. This chart shows the average 12-month analyst forecast, representing their collective speculative bet that the company's R&D platform will prove effective in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATXI-Avenue-Therapeutics&v=1772662148496 "A chart showing analyst consensus forecasts for the expected stock price. ATXI (Avenue Therapeutics)")
The difference between the consensus estimate and the actual stock price ATXI (Avenue Therapeutics)
Avenue Therapeutics (ATXI) is a biotech company focused on developing drugs for the treatment of central nervous system diseases. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of the risks and potential of the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATXI-Avenue-Therapeutics&v=1772662148502 "A chart showing the difference between the consensus forecast and the actual stock price. ATXI (Avenue Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Avenue Therapeutics (ATXI) is a biotech company seeking FDA approval for IV tramadol (a painkiller) for hospital use. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe R&D can succeed in the challenging painkiller market.
Analysts' consensus forecast for the overall market share price
Avenue Therapeutics (ATXI) is a clinical-stage biopharmaceutical company focused on pain treatment. They are trying to bring non-opioid analgesics to market. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Avenue Therapeutics
Avenue Therapeutics is a biotech R&D company focused on neuroscience (pain treatment). Their signature product is IV tramadol, which they unsuccessfully sought FDA approval for as an alternative to opioids in hospitals. This chart summarizes their battle with the FDA, reflecting their repeated rejections and their desperate fight for survival.
AKIMA Market Segment Index - Neuro
Avenue Therapeutics is a pharmaceutical company focused on neurology and pain management. They are developing drugs for the treatment of acute conditions in hospital settings. This chart compares their composite index to the sector, showing how their approach to hospital neurology compares to their competitors.
The AKIM Index for the overall market
Avenue Therapeutics is a specialty pharmaceutical company developing treatments for neurological disorders (spasticity, epilepsy). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this micro-cap story compares to overall economic trends.
